Literature DB >> 15000156

Surgical treatment of colorectal cancer metastasis.

Steven A Curley1, Francesco Izzo, Eddie Abdalla, J Nicholas Vauthey.   

Abstract

Colorectal cancer is one of the most common solid tumors affecting people around the world. A significant proportion of patients with colorectal cancer will develop or will present with liver metastases. In some of these patients, the liver is the only site of metastatic disease. Thus, surgical treatment approaches are an appropriate and important treatment option in patients with liver-only colorectal cancer metastases. Resection of colorectal cancer liver metastases can produce long-term survival in selected patients, but the efficacy of liver resection as a solitary treatment is limited by two factors. First, a minority of patients with liver metastases have resectable disease. Second, the majority of patients who undergo successful liver resection for colorectal cancer metastases develop recurrent disease in the liver, extrahepatic sites, or both. In this paper, in addition to the results of liver resection for colorectal cancer metastases, we will review the results of thermal ablation. Each of these surgical treatment modalities can produce long-term survival in a subset of patients with liver-only colorectal cancer metastases, whereas administration of systemic or regional chemotherapy rarely results in long-term survival in these patients. While surgical treatments provide the best chance for long-term survival or, in some cases, the best palliation in patients with colorectal cancer liver metastases, it is clear that further improvements in patient outcome will require multimodality therapy regimens. Modern surgical treatment of colorectal liver metastases can be performed safely with low mortality and transfusion rates, and surgical treatment should be considered in patients with disease confined to their liver.

Entities:  

Mesh:

Year:  2004        PMID: 15000156     DOI: 10.1023/a:1025875332255

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  13 in total

1.  Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.

Authors:  Apostolia M Tsimberidou; Stacy Moulder; Siqing Fu; Sijin Wen; Aung Naing; Agop Y Bedikian; Shawn Daring; Cynthia Uehara; Chaan Ng; Michael Wallace; Luis Camacho; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-04       Impact factor: 3.333

2.  APOBEC3G expression is correlated with poor prognosis in colon carcinoma patients with hepatic metastasis.

Authors:  Huanrong Lan; Ketao Jin; Meifu Gan; Shouxiang Wen; Tienan Bi; Shenkang Zhou; Naibiao Zhu; Lisong Teng; Wenjie Yu
Journal:  Int J Clin Exp Med       Date:  2014-03-15

3.  Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2.

Authors:  Obul R Bandapalli; Stephan Macher-Goeppinger; Peter Schirmacher; Karsten Brand
Journal:  Clin Exp Metastasis       Date:  2012-02-24       Impact factor: 5.150

4.  APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis.

Authors:  Qingqing Ding; Chun-Ju Chang; Xiaoming Xie; Weiya Xia; Jer-Yen Yang; Shao-Chun Wang; Yan Wang; Jiahong Xia; Libo Chen; Changchun Cai; Huabin Li; Chia-Jui Yen; Hsu-Ping Kuo; Dung-Fang Lee; Jingyu Lang; Longfei Huo; Xiaoyun Cheng; Yun-Ju Chen; Chia-Wei Li; Long-Bin Jeng; Jennifer L Hsu; Long-Yuan Li; Alai Tan; Steven A Curley; Lee M Ellis; Raymond N Dubois; Mien-Chie Hung
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

5.  A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.

Authors:  Apostolia M Tsimberidou; Siqing Fu; Chaan Ng; Jo Ann Lim; Sijin Wen; David Hong; Jennifer Wheler; Agop Y Bedikian; Cathy Eng; Michael Wallace; Luis H Camacho; Razelle Kurzrock
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

6.  Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement.

Authors:  Apostolia M Tsimberidou; Katherine Letourneau; Siqing Fu; David Hong; Aung Naing; Jennifer Wheler; Cynthia Uehara; Stephen E McRae; Sijin Wen; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-13       Impact factor: 3.333

7.  Microwave Ablation With a Triaxial Antenna: Results in ex vivo Bovine Liver.

Authors:  Christopher L Brace; Paul F Laeseke; Daniel W van der Weide; Fred T Lee
Journal:  IEEE Trans Microw Theory Tech       Date:  2005-01       Impact factor: 3.599

Review 8.  Surgical therapy for colorectal metastases to the liver.

Authors:  Timothy M Pawlik; Michael A Choti
Journal:  J Gastrointest Surg       Date:  2007-08       Impact factor: 3.452

9.  Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.

Authors:  Reza Kianmanesh; Stefano Scaringi; Jean-Marc Sabate; Benjamin Castel; Nathalie Pons-Kerjean; Benoit Coffin; Jean-Marie Hay; Yves Flamant; Simon Msika
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

Review 10.  Operative mortality after hepatic resection: are literature-based rates broadly applicable?

Authors:  Bolanle Asiyanbola; David Chang; Ana Luiza Gleisner; Hari Nathan; Michael A Choti; Richard D Schulick; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2008-02-12       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.